Kyverna and ElevateBio expand miv-cel manufacturing agreement
Kyverna signed a commercial manufacturing and supply agreement with ElevateBio for miv-cel, covering U.S. commercial production and global clinical supply.
The deal targets flexible, scalable capacity ahead of potential launches in stiff person syndrome and generalized myasthenia gravis.
ElevateBio cited a clinical manufacturing success rate above 98% for miv-cel across the companies’ three-year partnership.
Kyverna reiterated plans to complete a rolling BLA submission for miv-cel in stiff person syndrome in Q4 2026.
KYTX•
